Covered recipient · General Payments record
WARD J PAINE
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,572.57
59 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,070.22 | 49 |
| Travel and Lodging | $482.13 | 9 |
| Education | $20.22 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $855.63 | 18 |
| Abbott Laboratories | $192.39 | 10 |
| Lilly USA, LLC | $66.00 | 4 |
| Otsuka America Pharmaceutical, Inc. | $53.34 | 3 |
| Novo Nordisk Inc | $53.17 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $48.41 | 3 |
| Dexcom, Inc. | $45.79 | 3 |
| Organogenesis Inc. | $40.97 | 2 |
| Bayer Healthcare Pharmaceuticals Inc. | $35.90 | 2 |
| ABBVIE INC. | $31.20 | 2 |
| ACADIA Pharmaceuticals Inc | $29.41 | 2 |
| Exact Sciences Corporation | $20.99 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.35 | 1 |
| Novartis Pharmaceuticals Corporation | $19.25 | 1 |
| Mylan Specialty L.P. | $16.59 | 1 |
| AstraZeneca Pharmaceuticals LP | $15.68 | 1 |
| Amgen Inc. | $14.55 | 1 |
| GlaxoSmithKline, LLC. | $13.95 | 1 |
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WARD J PAINE
NPI 1518918614 · CMS profile ID 23826
Allopathic & Osteopathic Physicians / Internal Medicine
MORGANTOWN, WV
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518918614?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WARD J PAINE, NPI 1518918614, CMS profile ID 23826. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518918614?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). WARD J PAINE, NPI 1518918614, CMS profile ID 23826. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518918614?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- WARD J PAINE, NPI 1518918614, CMS profile ID 23826, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1518918614?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
59 matching records · $1,572.57 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–59 of 59.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $13.15 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125106900 | CMS |
| Dexcom, Inc. | $14.11 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153343523 | CMS |
| Amgen Inc. | $14.55 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117647725 | CMS |
| ABBVIE INC. | $13.37 | 02/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105170396 | CMS |
| ABBVIE INC. | $17.83 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105170394 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.68 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105537555 | CMS |
| Novo Nordisk Inc | $18.76 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097574777 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.95 | 01/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118042484 | CMS |
| Lilly USA, LLC | $13.15 | 01/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135477038 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $772,831.32 | 51 |
| PY2024 | Recipient | $28,819.67 | 5 |
| PY2024 | Principal investigator | $1,187,439.34 | 87 |
| PY2023 | Recipient | $7,075.62 | 2 |
| PY2023 | Principal investigator | $1,271,587.07 | 38 |
| PY2022 | Recipient | $26,286.00 | 1 |
| PY2022 | Principal investigator | $1,547,485.10 | 9 |
| PY2021 | Principal investigator | $60,761.58 | 5 |
| PY2020 | Principal investigator | $40,257.65 | 7 |
| PY2019 | Principal investigator | $202,568.24 | 14 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
51 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,835.00 | 11/26/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure | No dispute reported | 06/30/2026 | 1185555768 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $40,406.38 | 11/26/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) | No dispute reported | 06/30/2026 | 1185555774 |
| Principal investigator 1 | Genentech, Inc. | $3,330.00 | 09/24/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607677 |
| Principal investigator 1 | Genentech, Inc. | $7,872.00 | 09/05/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607703 |
| Principal investigator 1 | Genentech, Inc. | $170.00 | 09/03/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607680 |
| Principal investigator 1 | ModernaTX, Inc. | $53.58 | 08/28/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005845 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $63,335.20 | 08/07/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185555778 |
| Principal investigator 1 | Amgen Inc. | $20,470.00 | 08/01/2025 | Non-covered Recipient Entity IM SUPER HOLDINGS LLC DBA IMA CLINICAL RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246642531 |
| Principal investigator 1 | Genentech, Inc. | $1,298.00 | 07/11/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607693 |
| Principal investigator 1 | Genentech, Inc. | $196.00 | 07/02/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607646 |
| Principal investigator 1 | Genentech, Inc. | $170.00 | 07/02/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607701 |
| Principal investigator 1 | ModernaTX, Inc. | $18,331.33 | 06/20/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005831 |
| Principal investigator 1 | Genentech, Inc. | $2,700.00 | 06/18/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607608 |
| Principal investigator 1 | ModernaTX, Inc. | $9,590.82 | 05/28/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005833 |
| Principal investigator 1 | ModernaTX, Inc. | $1,450.80 | 05/28/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005835 |
| Principal investigator 1 | ModernaTX, Inc. | $28,989.08 | 05/28/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005839 |
| Principal investigator 1 | Eli Lilly and Company | $829.61 | 05/27/2025 | Non-covered Recipient Entity MEDEX HEALTHCARE RESEARCH INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187884750 |
| Principal investigator 1 | Genentech, Inc. | $1,154.00 | 05/21/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607616 |
| Principal investigator 1 | Genentech, Inc. | $5,000.00 | 05/07/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607612 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,867.00 | 05/02/2025 | Non-covered Recipient Entity IMA EVALUATIONS, INC. | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185555770 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,450.00 | 04/30/2025 | Non-covered Recipient Entity AGA CLINICAL TRIALS | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185555766 |
| Principal investigator 1 | ModernaTX, Inc. | $5,803.20 | 04/28/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005837 |
| Principal investigator 1 | ModernaTX, Inc. | $28,562.77 | 04/28/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005849 |
| Principal investigator 1 | ModernaTX, Inc. | $12,055.50 | 04/28/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005855 |
| Principal investigator 1 | Eli Lilly and Company | $2,792.22 | 03/25/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187883602 |
| Principal investigator 1 | ModernaTX, Inc. | $8,704.80 | 03/24/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005851 |
| Principal investigator 1 | ModernaTX, Inc. | $11,144.64 | 03/24/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005857 |
| Principal investigator 1 | Genentech, Inc. | $588.00 | 03/21/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607432 |
| Principal investigator 1 | Genentech, Inc. | $935.00 | 03/19/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607473 |
| Principal investigator 1 | Eli Lilly and Company | $15,446.00 | 03/11/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187881912 |
| Principal investigator 1 | Eli Lilly and Company | $1,202.00 | 03/10/2025 | Non-covered Recipient Entity M SUPER HOLDINGS LLC IMA EVALUATIONS LLC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187885766 |
| Principal investigator 1 | ModernaTX, Inc. | $5,427.92 | 02/27/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005829 |
| Principal investigator 1 | ModernaTX, Inc. | $27,710.15 | 02/27/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005847 |
| Principal investigator 1 | ModernaTX, Inc. | $2,601.40 | 02/27/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005853 |
| Principal investigator 1 | ModernaTX, Inc. | $40,131.42 | 02/27/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005859 |
| Principal investigator 1 | ModernaTX, Inc. | $7,254.00 | 02/27/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005861 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $26,224.73 | 02/26/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185555772 |
| Principal investigator 1 | Amgen Inc. | $8,030.70 | 02/25/2025 | Non-covered Recipient Entity IMA CLINICAL RESEARCH - WEST VIRGINIA | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246642553 |
| Principal investigator 1 | Eli Lilly and Company | $18,765.00 | 02/03/2025 | Non-covered Recipient Entity M SUPER HOLDINGS LLC IMA EVALUATIONS LLC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187885764 |
| Principal investigator 1 | Eli Lilly and Company | $65.00 | 01/31/2025 | Non-covered Recipient Entity M SUPER HOLDINGS LLC IMA EVALUATIONS LLC | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187884212 |
| Principal investigator 1 | Genentech, Inc. | $1,921.00 | 01/29/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607497 |
| Principal investigator 1 | ModernaTX, Inc. | $44,645.40 | 01/29/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005825 |
| Principal investigator 1 | ModernaTX, Inc. | $8,704.80 | 01/29/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005827 |
| Principal investigator 1 | ModernaTX, Inc. | $5,202.80 | 01/29/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005843 |
| Principal investigator 1 | ModernaTX, Inc. | $15,773.47 | 01/29/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005863 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $40,367.60 | 01/17/2025 | Non-covered Recipient Entity IMA EVALUATIONS, INC. | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185555776 |
| Principal investigator 1 | Genentech, Inc. | $255.00 | 01/13/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607465 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 01/13/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005841 |
| Principal investigator 1 | Eli Lilly and Company | $63,260.00 | 01/07/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187882626 |
| Principal investigator 1 | Eli Lilly and Company | $42,357.00 | 01/06/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187882676 |
| Principal investigator 1 | Eli Lilly and Company | $89,901.00 | 01/06/2025 | Non-covered Recipient Entity IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187883592 |